Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial.
Bruno Martins TomaziniLucas TramujasFernando Azevedo MedradoSamara Pinheiro do Carmo GomesKarina Leal NegrelliGabriela Souza MurinizeRenato Hideo Nakagawa SantosBruna Martins Pereira ViannaBruna Fornazieri PiottoThabata Silva VeigaBianca Rodrigues do SantosAna Clara Peneluppi HorakOlivia Mora Cavalcante LemosMarcela de Almeida LopesBeatriz Baptista OlicheskiDiego Lurentt CamponesLuiz Angelo Alencar PeixotoAline Dos Anjos Chaves BasilioOtavio Celso Eluf GebaraAna Tarina Alvarez LopesHumberto SaconatoNanci ValeisTamiris Abait MirandaLigia Nasi LaranjeiraEliana Vieira SantucciAaron Foster CarlinJeffrey David EskoPhillip Leo Stephan Marie GordtsSotirios TsimikasAlexandre Biasi CavalcantiPublished in: PloS one (2024)
Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.